Global Nucleic Acid and Oligonucleotide Therapeutics Market Growth (Status and Outlook) 2024-2030

Global Nucleic Acid and Oligonucleotide Therapeutics Market Growth (Status and Outlook) 2024-2030

Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.

The global Nucleic Acid and Oligonucleotide Therapeutics market size is projected to grow from US$ 12670 million in 2024 to US$ 15900 million in 2030; it is expected to grow at a CAGR of 3.9% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Nucleic Acid and Oligonucleotide Therapeutics Industry Forecast” looks at past sales and reviews total world Nucleic Acid and Oligonucleotide Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Nucleic Acid and Oligonucleotide Therapeutics sales for 2023 through 2029. With Nucleic Acid and Oligonucleotide Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid and Oligonucleotide Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Nucleic Acid and Oligonucleotide Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Nucleic Acid and Oligonucleotide Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nucleic Acid and Oligonucleotide Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleic Acid and Oligonucleotide Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid and Oligonucleotide Therapeutics.

United States market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Nucleic Acid and Oligonucleotide Therapeutics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Nucleic Acid and Oligonucleotide Therapeutics players cover Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acid and Oligonucleotide Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:
Antisense Oligonucleotides (ASO)
siRNA
mRNA

Segmentation by Application:
Neuromuscular Diseases
hATTR
COVID-19
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Antisense Oligonucleotides (ASO)
siRNA
mRNA

Segmentation by Application:
Neuromuscular Diseases
hATTR
COVID-19
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

Please note: The report will take approximately 2 business days to prepare and deliver.